TABLE 1 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET: PIPELINE ANALYSIS
TABLE 2 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 EUROPE TUBEROUS SCLEROSIS COMPLEX LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 EUROPE SPORADIC LAM IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE PNEUMOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE PLEURAL EFFUSIONS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE KIDNEY TUMOR IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE CHYLOTHORAX IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 EUROPE SWELLING & FLUID BUILD-UP IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 26 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 EUROPE HOSPITALS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE SPECIALTY CLINICS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE DIAGNOSTIC CENTER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 EUROPE HOME HEALTHCARE IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 35 EUROPE DIRECT TENDER IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 EUROPE HOSPITAL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE RETAIL PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 EUROPE ONLINE PHARMACIES IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 42 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 43 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 EUROPE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 EUROPE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 EUROPE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 EUROPE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 EUROPE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 EUROPE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 EUROPE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 EUROPE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 53 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 59 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 GERMANY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 GERMANY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 GERMANY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 GERMANY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 GERMANY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 GERMANY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 GERMANY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 GERMANY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 69 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 GERMANY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 GERMANY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 75 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 FRANCE TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 FRANCE MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 FRANCE MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 FRANCE BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 FRANCE LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 FRANCE DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 FRANCE IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 FRANCE LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 85 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 86 FRANCE ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 87 FRANCE PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 88 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 89 FRANCE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 90 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.K. TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.K. MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.K. MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 U.K. BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 U.K. LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 U.K. DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 U.K. IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 U.K. LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 101 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 102 U.K. ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 103 U.K. PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 104 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 105 U.K. LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 106 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 107 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 HUNGARY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 HUNGARY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 HUNGARY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 HUNGARY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 HUNGARY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 HUNGARY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 HUNGARY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 HUNGARY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 117 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 HUNGARY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 119 HUNGARY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 121 HUNGARY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 122 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 123 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 LITHUANIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 LITHUANIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 LITHUANIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 LITHUANIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 LITHUANIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 LITHUANIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 LITHUANIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 LITHUANIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 133 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 134 LITHUANIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 135 LITHUANIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 136 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 LITHUANIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 138 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 139 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 AUSTRIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 141 AUSTRIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 143 AUSTRIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 149 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 AUSTRIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 AUSTRIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 AUSTRIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 155 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 IRELAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 IRELAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 IRELAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 IRELAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 IRELAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 161 IRELAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 162 IRELAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 163 IRELAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 164 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 165 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 IRELAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 IRELAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 168 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 IRELAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 171 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 NORWAY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 NORWAY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 NORWAY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 NORWAY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 NORWAY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 NORWAY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 NORWAY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 NORWAY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 181 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 NORWAY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 NORWAY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 185 NORWAY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 186 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 187 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 188 POLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 POLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 POLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 POLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 POLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 POLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 POLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 POLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 197 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 198 POLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 199 POLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 201 POLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 202 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 203 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 ITALY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 205 ITALY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 206 ITALY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 207 ITALY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 208 ITALY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 209 ITALY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 210 ITALY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 211 ITALY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 212 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 213 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 214 ITALY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 215 ITALY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 216 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 217 ITALY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 218 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 219 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 SPAIN TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 SPAIN MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 SPAIN MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 SPAIN BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 SPAIN LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 SPAIN DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 SPAIN IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 SPAIN LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 228 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 229 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 SPAIN ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 SPAIN PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 232 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 233 SPAIN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 234 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 235 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 RUSSIA TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 RUSSIA MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 RUSSIA MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 RUSSIA BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 RUSSIA LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 RUSSIA DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 RUSSIA IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 RUSSIA LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 245 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 246 RUSSIA ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 247 RUSSIA PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 248 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 249 RUSSIA LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 250 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 251 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 252 TURKEY TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 253 TURKEY MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 254 TURKEY MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 255 TURKEY BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 256 TURKEY LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 257 TURKEY DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 258 TURKEY IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 TURKEY LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 261 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 262 TURKEY ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 263 TURKEY PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 264 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 265 TURKEY LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 266 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 267 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 NETHERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 NETHERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 NETHERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 NETHERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 NETHERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 NETHERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 274 NETHERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 275 NETHERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 276 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 277 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 278 NETHERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 279 NETHERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 280 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 281 NETHERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 282 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 283 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 SWITZERLAND TREATMENT IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 SWITZERLAND MEDICATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 SWITZERLAND MTOR INHIBITORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 SWITZERLAND BRONCHODILATORS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 SWITZERLAND LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 SWITZERLAND DIAGNOSIS IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 SWITZERLAND IMAGING TEST IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 SWITZERLAND LUNG BIOPSY IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 293 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 294 SWITZERLAND ORAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 295 SWITZERLAND PARENTERAL IN LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 296 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 297 SWITZERLAND LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 298 REST OF EUROPE LYMPHANGIOLEIOMYOMATOSIS (LAM) MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)